• Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...